Replies to post #8779 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

i think the fda will have no problem approving the drug bc its sorta in an unmet need category, theres already two approved drugs in the class, and it did meet the SPA, and likely works much better in some populations that others.....however, getting people and insurance companies to pay for the drug might be a problem. having said that, in some of the other classes of drugs like the vegfs and egfrs, some of the PFS and survival benefits are very similar to what the ridaforolimus results are...and large pharma think those drugs are the bees knees...so, who knows. tarceva comes to mind ...

http://www.drugs.com/clinical_trials/new-data-phase-iii-saturn-study-showed-tarceva-extended-survival-patients-advanced-non-small-cell-7842.html